跳至主要内容
临床试验/NCT03644498
NCT03644498
已完成
不适用

Risk of Muscle Damage in Cancer Patients Exposed to the Influenza Vaccine While Receiving Checkpoint Inhibitor Therapies: A Nested Case Control Study Using Claims Data

Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 1,056 人2018年5月2日
适应症Cancer

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Cancer
发起方
Bristol-Myers Squibb
入组人数
1056
试验地点
1
主要终点
Incidence of myositis
状态
已完成
最后更新
2年前

概览

简要总结

A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells

注册库
clinicaltrials.gov
开始日期
2018年5月2日
结束日期
2018年10月17日
最后更新
2年前
研究类型
Observational
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Treatment with a checkpoint inhibitor (CPI)
  • Age greater than or equal to 18 years on date of first claim for a CPI
  • ICD-9 or ICD-10 code for a malignancy within 180 days prior to the first claim for any CPI, and
  • Greater than or equal to 180 days of continuous pharmaceutical and medical benefit enrollment in the database prior to the first claim for any CPI

排除标准

  • Less than 18 years of age
  • Other protocol defined inclusion/exclusion criteria could apply

结局指标

主要结局

Incidence of myositis

时间窗: Approximately 7 years

Incidence of myocarditis

时间窗: Approximately 7 years

Incidence of rhabdomyolysis

时间窗: Approximately 7 years

研究点 (1)

Loading locations...

相似试验